Related Experiment Video

Updated: Nov 24, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.2K

Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes

Lauren G Kanapka1, R Paul Wadwa2, Marc D Breton3

  • 1Jaeb Center for Health Research, Tampa, FL.

Diabetes Care
|December 23, 2020
PubMed

Insights

The Control-IQ closed-loop control system safely improves glycemic control in children with type 1 diabetes. Improvements in time in range were observed from the first day of use and sustained for up to 28 weeks.

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Technology
  • Metabolic Diseases

Background:

  • Type 1 diabetes management in children requires continuous monitoring and intervention.
  • Closed-loop control (CLC) systems offer automated insulin delivery adjustments.
  • Previous studies indicated potential benefits of CLC systems in pediatric populations.

Purpose of the Study:

  • To further evaluate the safety and efficacy of the Control-IQ CLC system in children with type 1 diabetes.
  • To assess the long-term glycemic control improvements with CLC therapy.
  • To compare CLC performance against sensor-augmented pump (SAP) therapy.

Main Methods:

  • A 16-week randomized clinical trial (RCT) compared CLC with SAP therapy in 101 children (6-13 years) with type 1 diabetes.
  • Participants transitioned between therapies, forming SAP-CLC and CLC-CLC cohorts for subsequent evaluation.
  • Glycemic control metrics, including time in range (TIR) and time below range, were analyzed over 12 weeks post-RCT.

Main Results:

  • In the SAP-CLC cohort, mean TIR increased from 55% to 65% with CLC (P < 0.001).
  • 36% of participants achieved TIR >70% with CLC, compared to 14% with SAP (P = 0.03).
  • Significant improvements in TIR and reductions in time below 70 mg/dL were observed rapidly, with no severe hypoglycemia or DKA.

Conclusions:

  • The Control-IQ CLC system safely enhances glycemic control in children with type 1 diabetes.
  • Improvements in glycemic control are evident from the first day of CLC use.
  • Sustained glycemic control benefits were demonstrated through 28 weeks of CLC system utilization.
Abstract

More Related Videos

Quantitative and Temporal Control of Oxygen Microenvironment at the Single Islet Level11:49

Quantitative and Temporal Control of Oxygen Microenvironment at the Single Islet Level

Published on: November 17, 2013

9.4K
Control of Eating Behavior Using a Novel Feedback System04:48

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

11.3K

Related Concept Videos

Open and closed-loop control systems01:17

Open and closed-loop control systems

Control systems are foundational elements in automation and engineering. They are broadly categorized into open-loop and closed-loop systems. These classifications hinge on the presence or absence of feedback mechanisms, significantly influencing the system's performance, complexity, and application.
An open-loop control system operates without feedback from the output. It consists of two primary elements: the controller and the controlled process. The controller receives an input signal...
1.3K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.4K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
445
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
458
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
723
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.9K